Hepatitis Therapeutics Market

Hepatitis Therapeutics Market (Disease Type - Hepatitis A, Hepatitis B, Hepatitis C; Drug Class - Nucleotide Analog Reverse Transcriptase Inhibitor, NS5A Inhibitor, Multi-class Combination, Nucleotide Analog NS5B Polymerase Inhibitor, Interferon and Ribavirin; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL52665
  • Published On : Jan 2019
  • No. of Pages : 183
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Hepatitis Therapeutics Market

4. Market Overview
     4.1. Introduction
            4.1.1. Industry Evolution/Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1.Pipeline Analysis
     5.2.New Product Launch, Approvals & Patent Expiry
     5.3.Regulatory Scenario

6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type 
     6.1. Introduction & Definition
     6.2. Market Value Forecast, by Disease Type, 2016–2026
            6.2.1. Hepatitis A 
            6.2.2. Hepatitis B
            6.2.3. Hepatitis C
            6.2.4. Others 
     6.3. Market Attractiveness, by Disease Type

7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class 
     7.1. Introduction & Definition
     7.2. Market Value Forecast, by Drug Class, 2016–2026
                   7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            7.2.2. NS5A Inhibitor
            7.2.3. Multi Class Combination 
            7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            7.2.5. Interferon & Ribavirin 
            7.2.6. Others
     7.3. Market Attractiveness, by Drug Class

8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Market Value Forecast, by Distribution Channel, 2016–2026
            8.2.1. Hospital Pharmacies
            8.2.2. Retail Pharmacies 
            8.2.3. Online Pharmacies 
     8.4. Market Attractiveness, by Distribution Channel

9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
     9.1. Market Value Forecast, by Region
            9.1.1. North America 
            9.1.2. Europe 
            9.1.3. Asia Pacific 
            9.1.4. Latin America 
            9.1.5. Middle East & Africa 
     9.2. Market Attractiveness, by Country/Region

10. North America Hepatitis Therapeutics Market Analysis and Forecast
     10.1.Introduction
     10.2.Market Value Forecast, by Disease Type, 2016–2026
            10.2.1. Hepatitis A 
            10.2.2. Hepatitis B 
            10.2.3. Hepatitis C
            10.2.4. Others 
     10.3.Market Value Forecast, by Drug Class, 2016–2026
            10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            10.3.2. NS5A Inhibitor
            10.3.3. Multi Class Combination 
            10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            10.3.5. Interferon & Ribavirin 
            10.3.6. Others
     10.4.Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospital Pharmacies
            10.4.2. Retail Pharmacies 
            10.4.3. Online Pharmacies 
     10.5.Market Value Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6.Market Attractiveness, Analysis 
            10.6.1.By Disease Type 
            10.6.2. B Drug Class 
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Hepatitis Therapeutics Market Analysis and Forecast
     11.1.Introduction
     11.2.Market Value Forecast, by Disease, 2016–2026
            11.2.1. Hepatitis A 
            11.2.2. Hepatitis B 
            11.2.3. Hepatitis C
            11.2.4. Others 
     11.3.Market Value Forecast, by Drug Class, 2016–2026
            11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            11.3.2. NS5A Inhibitor
            11.3.3. Multi-class Combination 
            11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            11.3.5. Interferon & Ribavirin 
            11.3.6. Others
     11.4.Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospital Pharmacies
            11.4.2. Retail Pharmacies 
            11.4.3. Online Pharmacies 
     11.5.Market Value Forecast, by Country, 2016–2026
            11.5.1. Germany 
            11.5.2. U.K.
            11.5.3. France 
            11.5.4. Spain 
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6.Market Attractiveness, Analysis 
            11.6.1. By Disease Type 
            11.6.2. By Drug Class 
            11.6.3. By Distribution Channel 
            11.6.4. By Country

12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
     12.1.Introduction
     12.2.Market Value Forecast, by Disease Type, 2016–2026
            12.2.1. Hepatitis A 
            12.2.2. Hepatitis B 
            12.2.3. Hepatitis C
            12.2.4. Others 
     12.3.Market Value Forecast, by Drug Class, 2016–2026
            12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            12.3.2. NS5A Inhibitor
            12.3.3. Multi-class Combination 
            12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            12.3.5. Interferon & Ribavirin 
            12.3.6. Others
     12.4.Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospital Pharmacies
            12.4.2. Retail Pharmacies 
            12.4.3. Online Pharmacies 
     12.5.Market Value Forecast, by Country, 2016–2026
            12.5.1. Japan 
            12.5.2. China
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific 
     12.6.Market Attractiveness, Analysis 
            12.6.1. By Disease Type 
            12.6.2. By Drug Class 
            12.6.3. By Distribution Channel 
            12.6.4. By Country

13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
     13.1.Introduction
     13.2.Market Value Forecast, by Disease Type, 2016–2026
            13.2.1. Hepatitis A 
            13.2.2. Hepatitis B 
            13.2.3. Hepatitis C
            13.2.4. Others 
     13.3.Market Value Forecast, by Drug Class, 2016–2026
            13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            13.3.2. NS5A Inhibitor
            13.3.3. Multi-class Combination 
            13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            13.3.5. Interferon & Ribavirin 
            13.3.6. Others
     13.4.Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospital Pharmacies
            13.4.2. Retail Pharmacies 
            13.4.3. Online Pharmacies 
     13.5.Market Value Forecast, by Country, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6.Market Attractiveness, Analysis 
            13.6.1. By Disease Type 
            13.6.2. By Drug Class 
            13.6.3. By Distribution Channel 
            13.6.4. By Country

14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
     14.1.Introduction
     14.2.Market Value Forecast, by Disease Type, 2016–2026
            14.2.1. Hepatitis A 
            14.2.2. Hepatitis B 
            14.2.3. Hepatitis C
            14.2.4. Others 
     14.3.Market Value Forecast, by Drug Class, 2016–2026
            14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor 
            14.3.2. NS5A Inhibitor
            14.3.3. Multi-class Combination 
            14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor 
            14.3.5. Interferon & Ribavirin 
            14.3.6. Others
     14.4.Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospital Pharmacies
            14.4.2. Retail Pharmacies 
            14.4.3. Online Pharmacies 
     14.5.Market Value Forecast, by Country, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.5. Rest of Middle East & Africa
     14.6.Market Attractiveness, Analysis 
            14.6.1. By Disease Type 
            14.6.2. By Drug Class 
            14.6.3. By Distribution Channel 
            14.6.4. By Country

15. Competition Landscape
     15.1.Market Share Analysis, by Company (2017)
     15.2. Company Profiles
            15.2.1. Gilead Sciences, Inc.
            15.2.2. F. Hoffmann-La Roche, Ltd. 
            15.2.3. Bristol Myers Squibb 
            15.2.4. Merck & Co., Inc. 
            15.2.5. AbbVie Inc. 
            15.2.6. NATCO Pharma Limited 
            15.2.7. Zydus Cadila 
            15.2.8. Hetero Healthcare Limited 
            15.2.9. LAURUS Labs 
            15.2.10. Cipla, Inc.

List of Tables
 
Table 01: Pipeline Analysis
Table 02: Pipeline Analysis
Table 03: Pipeline Analysis
Table 04: New Product Launch, Approvals & Patent Expiry
Table 05: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026 2016–2026
Table 06: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 07: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 10: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 11: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 12: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 13: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 14: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 15: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 16: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 17: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 18: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 19: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 20: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 21: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 22: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 23: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 24: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 25: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 26: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 27: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 28: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026

List of Figures
 
Figure 01: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
Figure 03: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
Figure 04: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 05: Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
Figure 06: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 07: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016–2026
Figure 08: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016–2026
Figure 09: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016–2026
Figure 10: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11: Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018–2026
Figure 12: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 13: Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 14: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016–2026
Figure 15: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016–2026
Figure 16: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016–2026
Figure 17: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016–2026
Figure 18: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016–2026
Figure 19: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 20: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 21: Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 22: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 23: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 24: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 25: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
Figure 26: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 27: North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 29: North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018–2026
Figure 30: North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 31: North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 32: North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 33: North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 34: North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 35: North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 38: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 39: Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 40: Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 41: Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 42: Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 43: Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 44: Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 46: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 47: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 48: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 49: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 50: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 51: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 52: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 53: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 54: Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 56: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 57: Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 58: Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 59: Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 60: Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 61: Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 62: Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 64:  Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 65: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 66:  Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 67:  Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 68:  Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 69:  Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 70:  Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 71:  Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 72: Global Hepatitis Therapeutics Market Share, by Company, 2017

.